Xu Yixiang, Salazar Georgina To'a, Zhang Ningyan, An Zhiqiang
Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Antib Ther. 2019 Jan 21;2(1):22-32. doi: 10.1093/abt/tbz001. eCollection 2019 Jan.
T-cell receptor mimic (TCRm) antibodies combine the capacity of a T cell to target intracellular antigens with other capacities unique to antibodies. Neoantigens are abnormal proteins that arise as a consequence of somatic mutations. Technological advances promote the development of neoantigen-targeting therapies including TCRm antibody therapies. This review summarizes key characteristics of TCRm antibodies, in particular those targeting neoantigens, and further introduces discussion of obstacles that must be overcome to advance TCRm therapeutics.
T细胞受体模拟物（TCRm）抗体将T细胞靶向细胞内抗原的能力与抗体特有的其他能力结合在一起。新抗原是体细胞突变产生的异常蛋白质。技术进步推动了包括TCRm抗体疗法在内的新抗原靶向疗法的发展。本综述总结了TCRm抗体的关键特性，特别是那些靶向新抗原的特性，并进一步介绍了推进TCRm疗法必须克服的障碍的讨论。
